Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Trial crawled date : 2021 - 10 - 19 save search
Global IoT-Enabled Industrial Wearables Market to Reach $3.5 Billion by 2026
Published: 2021-10-19 (Crawled : 15:00) - prnewswire.com
SEKEY | $8.91 46K
|
Manufacturing
|
| O: 2.5%
H: 0.0%
C: -1.83%
VUZI P | $1.335 1.91% 140K
|
Electronic Technology
|
| O: 0.61%
H: 4.54%
C: 3.64%
KOPN | $1.01 4.85% 620K
|
Electronic Technology
|
| O: 1.06%
H: 2.95%
C: 2.11%
iot trial
First Wave BioPharma Announces FDA Clearance of IND Application for Phase 2a PASSPORT Trial of FW-ICI-AC as Treatment for Immune Checkpoint Inhibitor-Associated Colitis
Published: 2021-10-19 (Crawled : 15:00) - biospace.com/
FWBI | $3.12 2.4K
|
Manufacturing
|
| O: 6.23%
H: 1.38%
C: -3.1%
fda clearance treatment fda phase 2 biopharma application trial clearance phase 2b
With Market Size Valued at $1.3 Billion by 2026, it`s a Healthy Outlook for the Global Industrial Communication Gateways Market
Published: 2021-10-19 (Crawled : 14:15) - prnewswire.com
GIC | $41.15 -0.36% 1.5K
|
Retail Trade
|
| O: 0.65%
H: 2.29%
C: 1.97%
EMR | $110.07 0.27% 200K
|
Producer Manufacturing
|
| O: 0.7%
H: 0.15%
C: -0.02%
CSCO | News | $48.195 -0.26% 2.1M
|
Technology Services
|
| O: 0.18%
H: 0.89%
C: 0.81%
communication trial
Galera Announces Results of Phase 3 ROMAN Trial of Avasopasem for Radiotherapy-Induced Severe Oral Mucositis
Published: 2021-10-19 (Crawled : 14:00) - biospace.com/
GRTX | $0.194 480K
|
Health Technology
|
| O: -72.03%
H: 22.71%
C: 8.7%
therapy results phase 3 iot trial oral mucositis avasopasem roman trial
Lilly's Longest Diabetes Drug Trial Lowers A1C and Increases Weight Loss
Published: 2021-10-19 (Crawled : 14:00) - biospace.com/
LLY | News | $733.27 -1.67% 470K
|
Health Technology
|
| O: 0.03%
H: 1.46%
C: 1.36%
weight loss diabetes drug trial
Atea Pharmaceuticals Provides Update and Topline Results for Phase 2 MOONSONG Trial Evaluating AT-527 in the Outpatient Setting
Published: 2021-10-19 (Crawled : 14:00) - biospace.com/
AVIR | $3.705 -0.67% 33K
|
Health Technology
|
| O: -72.41%
H: 48.48%
C: 23.39%
at-527 phase 2 results topline trial
ImmunityBio Announces Primary Endpoint Met in a Second Indication in Bladder Cancer Trial with 57% Disease-Free Survival in Patients with BCG Unresponsive Papillary Disease
Published: 2021-10-19 (Crawled : 13:15) - nantkwest.com
IBRX | $5.435 -1.0% 1.8M
|
Manufacturing
|
| O: 0.9%
H: 2.89%
C: 1.78%
disease bladder cancer cancer trial bladder
Moleculin Receives Authorization from the Medicines and Healthcare Products Regulatory Agency (MHRA) to Commence Phase 1a Clinical Trial of WP1122 for the Treatment of COVID-19
Published: 2021-10-19 (Crawled : 13:00) - prnewswire.com
MBRX | $4.6 870
|
Health Technology
|
| O: 0.37%
H: 3.72%
C: 2.23%
covid treatment phase 1 trial phase 1b
VYNE Therapeutics Enrolls First Patient in Clinical Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic Dermatitis
Published: 2021-10-19 (Crawled : 13:00) - vynetherapeutics.com
VYNE | $2.39 3.02% 40K
|
Health Technology
|
| O: -0.88%
H: 4.42%
C: -1.77%
treatment atopic dermatitis dermatitis trial enroll
Inhibikase Therapeutics Announces Dosing of First Parkinson's Patient in its Phase 1b Clinical Trial of IkT-148009
Published: 2021-10-19 (Crawled : 12:15) - prnewswire.com
IKT | $1.63 3.16% 8.7K
|
Health Technology
|
| O: 4.0%
H: 7.14%
C: 5.49%
phase 1 ikt-148009 parkinson trial phase 1b phase 2b
Opthea Opens Patient Enrollment in the Asia-Pacific Region for the OPT-302 ShORe and COAST Phase 3 Trials in Wet AMD
Published: 2021-10-19 (Crawled : 11:00) - globenewswire.com
OPT | News | $3.36 1K
|
Health Technology
|
| O: 8.01%
H: 2.05%
C: -4.35%
trials phase 3 trial enroll
Entasis Therapeutics announces positive topline results for sulbactam-durlobactam (SUL-DUR) from Phase 3 ATTACK trial
Published: 2021-10-18 (Crawled : 00:00) - biospace.com/
ETTX | $2.19 -0.46% 0.46%
|
Health Technology
|
| O: 0.63%
H: 0.66%
C: -1.89%
positive results topline phase 3 trial
Celcuity Announces Clinical Trial Collaboration with University of Rochester Wilmot Cancer Center and Puma to Study Patients with Breast Cancer Brain Metastases
Published: 2021-10-18 (Crawled : 00:00) - biospace.com/
PBYI | $5.015 -2.24% 47K
|
Health Technology
|
| O: -0.17%
H: 0.83%
C: -1.99%
CELC | $17.225 -0.09% 5.2K
|
Commercial Services
|
| O: 0.55%
H: 1.42%
C: -3.61%
collaboration cancer breast cancer trial train brain metastases
Gainers vs Losers
| 66% | 34% |
Top 10 Gainers
CZOO | $11.44 129.26% 4.6M
|
AMST | $3.4 70.0% 51M
|
Technology Services
BOF | $1.78 52.14% 15M
|
CSSE 4 | $0.23 51.02% 46M
|
Consumer Services
TROO | $1.57 44.04% 2.8M
|
Manufacturing
RILY | $30.87 42.13% 7.8M
|
Finance
LICN | $0.76 35.71% 6.2M
|
MULN | News | $3.53 29.3% 4.8M
|
Information
RBBN 4 | $3.26 26.85% 1.2M
|
Electronic Technology
RCAT | $1.52 26.67% 1.3M
|
Information
Your saved searches
Save your searches and get alerts when important news are released.